Soliris
(Eculizumab)
Provider Summary
Primary Uses
Complement-mediated disorders (indication depends on diagnosis, e.g., PNH, aHUS, gMG, NMOSD) per label and payer criteria.
Mechanism of action
Terminal complement inhibitor (binds C5), preventing formation of membrane attack complex.
Pre-treatment / baseline requirements
Meningococcal vaccination (and additional vaccines per PI) and REMS enrollment; screen for active infection; counsel on urgent meningococcal symptoms.
Common side effects
Headache, nasopharyngitis/URI, nausea.
Serious adverse effects / key risks
Boxed warning: life-threatening meningococcal infections/sepsis; other serious infections with encapsulated bacteria.
Referral requirements
Standard infusion referral form + drug-specific checklist
REMS & vaccination
Meningococcal vaccination is required per REMS. If treatment must start before vaccines are effective, follow prescriber PI guidance regarding prophylactic antibiotics and urgent-start protocols.
Patient & Caregiver Education
Meningitis risk
vaccination is required. Seek emergency care for sudden fever, severe headache, stiff neck, rash, confusion, or sensitivity to light.
What it treats
Complement-mediated disorders
How it works
Blocks complement (C5), preventing immune-mediated damage in certain rare conditions.
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review
Common side effects
Headache, nasopharyngitis/URI, nausea.
Get urgent help for
Boxed warning: life-threatening meningococcal infections/sepsis; other serious infections with encapsulated bacteria.